Protagen to use UNIarray platform to discover MS biomarkers for
14 April 2011
Dortmund-based Protagen AG, a specialist in in-vitro
diagnostics and GMP-compliant protein analysis, has announced that it
will be using the UNIarray Platform to help discover biomarkers in
relapsing remitting multiple sclerosis for Biogen Idec, Inc.
Under the terms of the agreement, Protagen will apply its UNIarray
technology platform and expertise in autoantibody research to
support retrospective analysis of samples from a Biogen Idec
clinical trial for the purpose of finding predictive and response
biomarkers associated with multiple sclerosis (MS) therapy.
UNIarray is a technology platform for the development of novel
diagnostics based on indication specific autoantibody patterns in
“There is an acute need to discover possible response and
non-response biomarkers in MS using genomic and proteomic level
markers,” said Dr Peter Schulz-Knappe, CSO of Protagen AG.
“Autoantibody signatures play an increasingly important role as a
technology platform that could be used to identify patients for
optimized treatment efficacy and to monitor disease progression.”
“Pharmaceutical companies recognize more and more the importance
of autoantibody signatures for drug development, and Protagen
provides the right technology and unique expertise for
collaborations in this area”, said Dr Stefan Müllner, CEO.